Macitentan in chronic thromboembolic pulmonary hypertension (CTEPH): experience from the OPUS registry

N. Kim (La Jolla, United States of America), R. Channick (Boston, United States of America), V. Mclaughlin (Ann Arbor, United States of America), J. Mcconnell (Louisville, United States of America), D. Poch (La Jolla, United States of America), M. Brand (Allschwil, Switzerland), E. Muros-Le Rouzic (Allschwil, Switzerland), M. Selej (South San Francisco, United States of America), K. Chin (Dallas, United States of America)

Source: International Congress 2018 – Chronic thromboembolic pulmonary hypertension
Session: Chronic thromboembolic pulmonary hypertension
Session type: Oral Presentation
Number: 4945
Disease area: Pulmonary vascular diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Kim (La Jolla, United States of America), R. Channick (Boston, United States of America), V. Mclaughlin (Ann Arbor, United States of America), J. Mcconnell (Louisville, United States of America), D. Poch (La Jolla, United States of America), M. Brand (Allschwil, Switzerland), E. Muros-Le Rouzic (Allschwil, Switzerland), M. Selej (South San Francisco, United States of America), K. Chin (Dallas, United States of America). Macitentan in chronic thromboembolic pulmonary hypertension (CTEPH): experience from the OPUS registry. 4945

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
First international registry on chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease
Year: 2008


Initial results of the UK audit of chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Eur Respir J 2007; 30: Suppl. 51, 486s
Year: 2007

Management of chronic thromboembolic pulmonary hypertension (CTEPH): A physician-based perception study
Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment
Year: 2012


The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study
Source: Eur Respir J 2006; 28: 138-143
Year: 2006



Survival in patients with chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Eur Respir J 2005; 26: Suppl. 49, 272s
Year: 2005

Macitentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): results from the randomised controlled MERIT study
Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials
Year: 2017



Chronic thromboembolic pulmonary hypertension (CTEPH) and beyond
Source: Annual Congress 2011 - Ceremony for Pulmonary Arterial Hypertension Award (supported by Actelion) followed by Pulmonary Hypertension in the Clinic Grand Round - an interactive session
Year: 2011


The incidence of chronic thromboembolic pulmonary hypertension (CTEPH): a 25-year population-based study
Source: Eur Respir J 2003; 22: Suppl. 45, 462s
Year: 2003

Prevalence of chronic thromboembolic pulmonary hypertension (CTEPH) in patients after pulmonary embolism
Source: International Congress 2018 – Clinical aspects of pulmonary hypertension
Year: 2018

Incidence and outcomes of haemoptysis in patients with operable and non-operable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)
Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension
Year: 2016


Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015



Sequential multimodal therapy in patients with chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension
Year: 2020


The course of chronic thromboembolic pulmonary hypertension (CTEPH) in anticoagulated patients not eligible for pulmonary endarterectomy
Source: Eur Respir J 2002; 20: Suppl. 38, 237s
Year: 2002

Riociguat in chronic thromboembolic pulmonary hypertension (CTEPH): ERS/ESC risk assessment in CHEST
Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension
Year: 2016


Open label study of bosentan in chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2004; 24: Suppl. 48, 706s
Year: 2004

Prevalence of relapses and chronic thromboembolic pulmonary hypertension (CTEPH) in patients with pulmonary embolism (PE)
Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology
Year: 2016


Thrombophilic risk factors for chronic thromboembolic pulmonary hypertension (CTEPH) in Korea
Source: International Congress 2015 – Pulmonary circulation: pulmonary embolism and chronic thromboembolic pulmonary hypertension
Year: 2015

Bosentan for inoperable chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 399s
Year: 2006

Are we screening survivors of acute pulmonary embolism (PE) for chronic thromboembolic pulmonary hypertension (CTEPH)?
Source: Annual Congress 2011 - Clinical features of pulmonary thromboembolism
Year: 2011

Angiogenesis in chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Annual Congress 2012 - Pulmonary circulation: acute and chronic pulmonary embolism
Year: 2012